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Head and neck squamous cell carcinoma (HNSCC) is the sixth most
common cancer worldwide, and several molecular pathways that
underlie the molecular tumorigenesis of HNSCC have been iden-
tified. Among them, amplification or overexpression of ΔNp63 iso-
forms is observed in the majority of HNSCCs. Here, we unveiled a
ΔNp63-dependent transcriptional program able to regulate the
metabolism and the signaling of hyaluronic acid (HA), the major
component of the extracellular matrix (ECM). We found that
ΔNp63 is capable of sustaining the production of HA levels in cell
culture and in vivo by regulating the expression of the HA syn-
thase HAS3 and two hyaluronidase genes, HYAL-1 and HYAL-3. In
addition, ΔNp63 directly regulates the expression of CD44, the
major HA cell membrane receptor. By controlling this transcrip-
tional program, ΔNp63 sustains the epithelial growth factor recep-
tor (EGF-R) activation and the expression of ABCC1 multidrug
transporter gene, thus contributing to tumor cell proliferation
and chemoresistance. Importantly, p63 expression is positively cor-
related with CD44, HAS3, and ABCC1 expression in squamous cell
carcinoma datasets and p63-HA pathway is a negative prognostic
factor of HNSCC patient survival. Altogether, our data shed light
on a ΔNp63-dependent pathway functionally important to the
regulation of HNSCC progression.
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The cross-talk between cells and the components of the ex-tracellular matrix (ECM) is fundamental in multicellular
organisms and regulates several biological processes in both
physiological and pathological conditions (1). Hyaluronic acid
(HA), the major component of the ECM, is a nonsulfated, linear
glycosaminoglycan (GAG), which not only contributes to tissue
hydration and proper tissue architecture, but also plays impor-
tant biological functions, including control of cell proliferation,
cell motility, cell adhesion, survival, and inflammation (2, 3).
These cellular events are mainly mediated by HA binding to
specific cell-surface receptors, including CD44, the most com-
mon and ubiquitous expressed HA receptor (4). In mammals,
HA synthesis occurs on the cellular plasma membrane by means
of three hyaluronan synthase isoenzymes (HAS1, HAS2, and
HAS3) that extrude the growing HA polymer into the peri-
cellular or the extracellular space (3, 5).
HA synthesis is counteracted by a degradative pathway that
clears HA by endocytic uptake and/or HA hydrolysis (6). In
humans, there are six hyaluronidase (HYAL) genes (HYAL-1–4,
HYAL-P1, and the sperm-specific PH-20). Among them, HYAL-1
and HYAL-2 are the best characterized HYALs and they can have
different catalytic properties (7).
Based on its role in important biological processes, it is not
surprising that deregulation of HA metabolism and signaling are
common events in several pathological conditions such as tumor
development (8). Deregulation of HA production during tumor
progression is often associated with alterations of the enzymes
that regulate HA synthesis and degradation. Overexpression of
either HAS2 or HAS3 is associated with higher malignancy or
metastasis in several tumor types, such as breast and prostate
carcinomas (9, 10). Although these data indicate that de-
regulation of HA production is tightly linked with tumor pro-
gression, our knowledge of the molecular mechanism(s) linking
oncogenes and HA metabolism has not yet been elucidated.
p63 is a transcription factor belonging to the p53 family, and it
is expressed as distinct protein isoforms (11, 12). ΔNp63 iso-
forms are the most expressed variants in the basal cells of
stratified and glandular epithelia, and its overexpression and/or
genomic amplification is observed in up to 80% of squamous cell
carcinomas (SCCs) of the head and neck, skin, lung, and esoph-
agous (13). Moreover, several genetic alterations occurring in
head and neck squamous cell carcinoma (HNSCC), such asNOTCH1
mutation and ACTL6A amplification, favors p63 transcriptional
activity (14, 15). At molecular level, ΔNp63 isoforms, although
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lacking a canonical transcriptional activation domain, are endowed
with an alternative activation domain that enable them to stimulate
the expression of several target genes involved in the regulation of
stemness, cell migration, invasion, and cell adhesion (16–18).
However, ΔNp63 isoforms are also able to repress the transcrip-
tion of several target genes by different mechanisms (19, 20).
Here, we report evidence demonstrating that ΔNp63 supports
HNSCC proliferation and chemoresistance by modulating epithelial
growth factor receptor (EGF-R) activation and the expression of
the ABC transporter ABCC1 in a HA-dependent manner.
Results
ΔNp63 Regulates the Expression of HA Metabolism Genes. During
tumorigenesis, extensive remodeling of the ECM supports and
enhances tumor growth. To identify novel p63 target genes po-
tentially regulating ECM in HNSCC, we combined microarray
data performed in A253 cell line upon p63 depletion (Supporting
Information) with coexpression studies in human primary SCC
datasets, searching for ECM-related genes whose expression is
linked with that of p63. By cross-analyzing these data, we focused
our attention on the HA synthase HAS3 and the hyaluronidase
HYAL-1. We found that HAS3 expression is positively correlated
with that of TP63 in HNSCC, esophageal carcinoma, and lung
squamous cancer datasets (Fig. S1A). Silencing of p63 markedly
decreased HAS3 expression in A253, Detroit-562, and FaDu cells
(Fig. 1A and Fig. S1B). These HNSCC cell lines mainly express
the ΔNp63 isoforms (Fig. S1C), suggesting that these p63 isoforms
might regulate HAS3 expression. Accordingly, the specific de-
pletion of ΔNp63 isoforms efficiently decreased HAS3 expression
at mRNA and protein levels (Fig. 1B and Fig. S1D). As a com-
plementary approach, we found that the ectopic expression of
ΔNp63α in SCC-9 cells, in which endogenous p63 levels are
undetectable (Fig. S1E), dramatically increases HAS3 mRNA
(Fig. S1F). We also confirm the p63-dependent regulation of
HAS3 expression in a xenotransplantation experiment. We in-
oculated FaDu cells stably expressing a doxycycline-inducible
shp63 RNA in nude athymic mice. p63 silencing upon doxycy-
cline treatment markedly decreased the proliferative capacity
in vitro (Fig. S2) and the growth of xenotransplanted tumors
(Fig. 1C). Importantly, the expression of HAS3 mRNA is sig-
nificantly decreased in p63-silenced tumors (Fig. 1D). To further
investigate the mechanism of the ΔNp63-dependent regulation
of HAS3 expression, we verified whether ΔNp63 is able to bind
to the HAS3 locus. To this aim, we performed a ChIP experiment
in FaDu cells relying on ChIP-seq data performed on human
primary keratinocytes (NHEK) (Fig. S3A). We found that en-
dogenous ΔNp63 is able to occupy a p63-binding site (p63 BS)
located in the HAS3 promoter site, at −5 kb from the transcription
start site (TSS) (Fig. 1E). Furthermore, exogenous ΔNp63α
greatly enhanced the HAS3 promoter-mediated luciferase activity
(Fig. S3B).
In addition to HAS3, our microarray data revealed that
p63 silencing affects HYAL-1 mRNA levels (Supporting In-
formation). In this case, we observed that the expression of
HYAL-1 is increased upon p63 silencing at both mRNA and
protein levels (Fig. 1F). p63 depletion also increased the mRNA
levels of HYAL-3, another member of the hyaluronidases family.
Notably, HYAL-1 expression is also augmented in explanted
tumors upon p63 silencing (Fig. 1G). HYAL-1 and HYAL-3
genes are clustered together on chromosome 3p21.3, and we
found that endogenous ΔNp63 is able to bind to two p63-binding
sites, p63 BS#1 and BS#2, located in the HYAL-3 promoter site
and in the 3′-end of HYAL-1 gene, respectively (Fig. 1H and Fig.
S3C). Altogether, these results indicated that the HA synthase
HAS3 and the hyaluronidases HYAL-1 and HYAL-3 are bona
fide ΔNp63 transcriptional target genes in vitro and in vivo.
Fig. 1. ΔNp63 directly induces the expression of the HA-related genes. (A) HAS3 and p63 mRNA levels were quantified by qRT-PCR in the indicated HNSCC
cancer cell lines transfected with scramble (SCR) or p63 siRNA (sip63) oligos. Bars represent the mean of three technical replicates (n = 3, PCR runs) ± SD and
are representative of two independent experiments (n = 2 biological replicates). *P < 0.05. (B) Total protein lysates or purified membrane-bound proteins of
FaDu cells transfected with SCR, sip63, ΔNp63 (siΔNp63), or HAS3 siRNA oligos (siHAS3) were subjected to immunoblotting using antibodies to the indicated
proteins. (C) FaDu cells stably infected with doxycycline inducible shp63 expression particles (polyclonal population) were injected into the dorsal flank region
of athymic female nude mice (n = 6 per group). The tumor volume growth curves are shown as mean ± SEM on the Left. Images of the explanted tumors are
shown on the Right. (D) Total RNA extracted by untreated (shp63 off, n = 6) or doxycycline treated mice (shp63 on, n = 6) was utilized for qRT-PCR analysis of
the absolute expression of HAS3 mRNA. **P < 0.01. (E) ChIP analysis of endogenous ΔNp63 occupancy at the p63 binding site of HAS3 locus. (F) HYAL-1,
HYAL-2, and HYAL-3 mRNA levels were measured by qRT-PCR (Left) in FaDu cells transfected as in A). Bars represent the mean of three technical replicates
(n = 3, PCR runs) ± SD and are representative of two independent experiments (n = 2 biological replicates). *P < 0.05. In parallel, total protein lysates were
analyzed by immunoblotting using antibodies to the indicated proteins (Right). (G) HYAL-1 mRNA levels were quantified by qRT-PCR in explanted tumors as
described in D. (H) ChIP analysis of endogenous ΔNp63 occupancy at the p63 BS#1 and BS#2 of Hyals loci.
Compagnone et al. PNAS | December 12, 2017 | vol. 114 | no. 50 | 13255
M
ED
IC
A
L
SC
IE
N
CE
S
ΔNp63 Controls Hyaluronic Acid Levels. In light of the finding that
ΔNp63 is able to transcriptionally regulate genes involved in HA
metabolism, we tested whether ΔNp63 was capable of regulating
HA levels. The HA polymer is synthesized by the HA synthases
and extruded into the pericellular or the extracellular space.
We stained pericellular HA by immunofluorescence using the
high-affinity HA binding protein HABP, and we found that
ΔNp63 depletion decreases the levels of pericellular HA (Fig.
S4A). To quantify this effect, we measured HA levels in cell
medium by ELISA, and we confirmed that ΔNp63-depleted cells
display a marked reduction of HA levels in FaDu and A253 cells
(Fig. 2A and Fig. S4B), similarly to the HAS3-silenced cells (Fig.
S4C). Conversely, we found that the ectopic expression of
ΔNp63α isoform increases HA cellular levels (Fig. 2B). To fur-
ther validate the correlation between p63 and HA levels, we
performed an immunohistochemistry (IHC) staining of p63 and
HA in a HNSCC tissue microarray (TMA). We first confirmed
the specificity of HABP probe in tumor tissues by pretreating the
section with Streptomyces hyaluronidase (Fig. S4D). Although
HA can be produced by stromal and tumor cells, we observed a
correlation between the expression of p63 and the tumor-
associated HA content in 57 tumor samples (Fig. 2 C and D).
In support of these data, we found that HA tumor-associated
levels are markedly decreased in xenograft tumors upon silencing
of p63 (Fig. 2E). Collectively, these results indicated that
ΔNp63 is able to regulate HA cellular levels, likely via tran-
scriptional regulation of HAS3.
ΔNp63 Directly Induces the Expression of the HA Receptor CD44.
CD44 is the most tumor-relevant HA receptor, and de-
regulation of the expression of its variant isoforms is associated
with advanced diseases and chemoresistance in HNSCC (4, 21).
By analyzing coexpression data in esophageal and lung squamous
carcinoma datasets, we found that CD44 mRNA expression is
positively correlated with that of TP63 (Fig. S5A). To validate
these data in human HNSCC tissues, we analyzed p63 and
CD44 protein levels by IHC in the HNSCC TMA. We observed a
positive correlation between p63 and CD44 expression (Fig. 3 A
and B). Importantly, gain or loss of function of ΔNp63 expres-
sion markedly affected the expression of CD44 at mRNA and
protein levels (Fig. 3 C and D and Fig. S5 B and C). Conversely,
the expression of RHAMM, another well-characterized HA re-
ceptor, is not affected by ΔNp63 depletion (Fig. S5D). These
transcriptional effects are likely due to a direct binding of
ΔNp63 on the CD44 locus. Indeed, by ChIP assay, we demon-
strated the ability of endogenous ΔNp63 to bind two p63-binding
sites, p63 BS#1 and p63 BS#2 located in the promoter region
and in the first intron of CD44 gene, respectively (Fig. 3E and
Fig. S5E). All together these results demonstrated that ΔNp63 is
able to directly regulate the expression of CD44 by physically
recognizing two p63-binding elements located in the CD44 locus.
The ΔNp63-HA Pathway Regulates EGF-R Activation. Since the HA/
CD44 interaction promotes the activation of receptor tyrosine
kinases (RTKs) (22, 23), we tested whether ΔNp63 is capable of
favoring RTKs activation in a HA-dependent manner. By using a
RTK signaling antibody array, we found that among several
RTKs and signaling nodes, tyrosine phosphorylation of EGF-R
and the activation of some downstream effectors, including Akt,
ERK1/2, and S6 ribosomal protein, are markedly decreased
upon p63 silencing in A253 and FaDu cells (Fig. S6A). We val-
idated these data using two different p63 targeting siRNA oligos,
which are both able to reduce EGF-R phosphorylation in several
HNSCC cell lines (Fig. 4A and Fig. S6B). In addition to EGF-R
phosphorylation, ΔNp63 depletion reduced the phosphorylation
of ErbB2, an ErbB family member whose activation is stimulated
by the HA/CD44 complex (23).
To investigate whether the ΔNp63-HA pathway might affect the
activation of the EGF-R, first we tested the effect of 4-methyl-
umbelliferone (4-MU), a chemical inhibitor of the enzymatic activity
of the HAS synthases (24), on EGF-R phosphorylation. We found
that 4-MU treatment markedly reduces the phosphorylation of EGF-
R and ErbB2 in A253 and FaDu cells, concomitantly with a decrease
of the pericellular HA amount (Fig. 4B and Fig. S6C). Similarly,
depletion of HAS3 gene expression by siRNA decreased EGF-R
phosphorylation in HNSCC cells (Fig. 4C and Fig. S6D). In a re-
verse experiment, overexpression of ΔNp63α or HAS3 increased
EGF-R phosphorylation (Fig. 4D and Fig. S6E). Importantly,
HAS3 inhibition by 4-MU treatment reverted the ability of exoge-
nous ΔNp63 to enhance the activation of EGF-R, Akt, and ERK1/2
(Fig. 4E). Since EGF-R transduction pathway activates proliferative
signals, we measured the proliferative capabilities of ΔNp63 or
HAS3 silenced cells by a cell counting assay. We found that the
siRNA-mediated depletion of HAS3 results in a decrease of cell
proliferation (Fig. 4F). All together, these observations indicated
that ΔNp63 favors the activation of oncogenic signals of EGFR
by, at least in part, modulating the HA/CD44 pathway.
Fig. 2. ΔNp63 controls HA levels. (A) FaDu cells were transfected with
scramble (SCR) or p63 siRNA oligos (sip63). Forty-eight hours after trans-
fection, growth medium of transfected cells was utilized to quantitatively
measure the levels of extracellular HA by ELISA assay. HA intracellular levels
were normalized against the number of cells (1 × 105). Bars represent the
mean of three technical replicates (n = 3) ± SD and are representative of two
independent experiments (n = 2 biological replicates). *P < 0.05. (B) SCC-
9 cells infected with empty or ΔNp63-expressing lentiviral particles were
analyzed as in A. (C) Representative images of IHC analysis of p63 and HA
staining in HNSCC tissues. Red boxes indicate higher-magnification images.
(D) Correlation plot of p63 and HA H scores in 57 human HNSCC tumor
samples including 50 cases of squamous cell carcinoma and 7 adenoid cystic
carcinomas. Pearson’s correlation coefficient (r) and the P value of the cor-
relation study are reported. (E) Representative images of IHC analysis of
p63 and HA staining in mouse xenograft tumor tissues upon p63 depletion.
13256 | www.pnas.org/cgi/doi/10.1073/pnas.1711777114 Compagnone et al.
ΔNp63/HA Axis Regulates ABC Drug Transporter Expression, and It Is a
Negative Prognostic Factor for HNSCC Patient Survival. The HA/
CD44 interaction modulates the chemosensitivity of cells to
various antineoplastic agents (21). Therefore, we tested whether
deregulation of the ΔNp63-HA axis might impact the chemo-
sensitivity of HNSCC cells toward the cytotoxic effect of sub-
lethal doses of doxorubicin and cisplatin. We found that upon
chemotherapeutic agent treatment, p63 or HAS3 silencing in-
creases the percentage of apoptotic cells and the cleavage of
PARP, an apoptotic marker (Fig. 5A and Fig. S7A). A similar
effect was observed in cells treated with the HAS inhibitor 4-MU
(Fig. S7B). As a complementary approach, we tested whether the
ectopic expression of ΔNp63 might exert a prosurvival effect in
cells exposed to doxorubicin. We found that the ectopic expression
of ΔNp63α in SCC-9 cells inhibits the doxorubicin-mediated ap-
optosis, an effect which is partially suppressed by the inhibition of
the HAS3 activity by 4-MU (Fig. 5B and Fig. S7 C and D), sug-
gesting that the ΔNp63-mediated prosurvival action is, at least in
part, mediated by its ability to regulate HA metabolism.
One potential mechanism underlying the chemoresistance
action of the HA/CD44 interaction is through the modulation of
the ATP-binding cassette (ABC) drug transporter expression (25,
26). Therefore, we screened HNSCC cell lines for the expression
of different ABC transporters, and we identified ABCC1 as the
main ABC transporter expressed in HNSCC cell lines (Fig. S7E).
Notably, ΔNp63 depletion, similarly to HAS3 depletion, reduced
ABCC1 mRNA levels in HNSCC cells (Fig. 5C). On the contrary,
the expression of ABCB3 transporter was not affected by
ΔNp63 or HAS3 depletion (Fig. S7F). In agreement with these
data, we found that TP63/ABCC1 and HAS3/ABCC1 coex-
pression is positively correlated in HNSCC dataset as well as in
esophageal SCC (Fig. S7G).
Based on these results, we can postulate that the p63/HA axis
would act as a negative prognostic factor in patients with
HNSCC. We therefore analyzed the overall patient survival of
two groups of HNSCC patients: those displaying high p63/
HAS3 coexpression and those with low coexpression (Fig. 5D,
Lower). We found that patients displaying high p63 and
HAS3 coexpression show a decrease of the overall survival
compared with those with low expression (Fig. 5D). All together,
these findings indicated that p63-HA pathway is a negative
Fig. 4. ΔNp63-HA pathway favors receptor tyrosine kinase activation. (A)
A253 cells were transfected with scramble (SCR) or two distinct siRNA oligos
targeting different regions of p63 mRNA (sip63#1 and sip63#2). Protein ly-
sates of transfected cells were immunoblotted utilizing the antibodies for
the indicated proteins. (B) FaDu cells were treated with the indicated concen-
tration of 4-MU for 24 h, and then protein lysates were immunoblotted for the
indicated proteins. (C) FaDu cells were transfected with SCR, HAS3 (siHAS3), or
sip63, and after 48 h, protein lysates were immunoblotted for the indicated
proteins. (D) A253 cells were infected with Flag-tagged HAS3 expressing viral
particles, and after 48 h, protein lysates were immunoblotted for the indicated
proteins. (E) SCC-9 cells were infectedwith empty or ΔNp63 expressing lentiviral
particles. Twenty-four hours after infection, cells were treated with 4-MU for
24 h and then protein lysates were immunoblotted for the indicated proteins.
(F) FaDu cells were plated in 6 wells (8 × 105 cells per well), and after 24 h,
transfected with SCR, siHAS3, or sip63. Six days after transfection, cells were
counted by Trypan blue dye exclusion in triplicate. Data are shown as the
mean ± SD (n = 3); *P < 0.05.
Fig. 3. ΔNp63 regulates the expression of the HA receptor CD44. (A) Rep-
resentative images of IHC analysis of CD44 and TP63 expression in HNSCC
tissues. Red boxes indicate higher-magnification images. (B) Correlation plot of
p63 and CD44 H-scores in 56 human HNSCC tumors including 49 cases of
squamous cell carcinoma and 7 adenoid cystic carcinomas. Pearson’s correla-
tion coefficient (r) and the P value of the correlation study are indicated. (C)
FaDu cells transfected with scramble (SCR) p63 (sip63), or ΔNp63-specific siRNA
oligos (siΔNp63) were analyzed by immunoblotting using the antibodies for
the indicated proteins. (D) FaDu cells treated as in C were analyzed for the
expression of CD44 by qRT-PCR. Bars represent the mean of three technical
replicates (n = 3, PCR runs) ± SD and are representative of two independent
experiments (n = 2 biological replicates). *P < 0.05. (E) ChIP analysis of en-
dogenous ΔNp63 occupancy at the p63 BS#1 and BS#2 in the CD44 locus.
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prognostic factor of patient survival and it might be functionally
important for HNSCC progression.
Discussion
HNSCCs are characterized by high mortality rate and intrinsic
chemoresistance (13, 27). Overexpression and/or amplification
of the TP63 locus is observed in the majority of invasive HNSCC
(28). Here, we not only identify an HA-related transcriptional
program directly regulated by ΔNp63 in HNSCC, but also pro-
vide a demonstration that this program is functionally important
to molecularly link ΔNp63 activity with two critical pathways in
HNSCC biology: EGF-R signaling and chemoresistance. We
demonstrated that ΔNp63 sustains HA signaling by directly
regulating the expression of HAS3, HYALs, and CD44 (see
proposed model, Fig. 5E). In human tumors, HA is pivotal for
various aspects of tumors pathobiology (29, 30), and the bi-
ological outcome of tumor-associated HA accumulation vary and
likely depends not only on its levels but also on the size of HA
polymers (31). Intriguingly, HAS3 synthesizes low molecular
weight chains of HA that have been associated with activation of
proliferative signals (32). Accordingly, the overexpression of
HAS3 in several tumors is associated with higher malignancy
(33), and HAS3 knockdown negatively impacts esophageal tu-
mor growth in vivo (34). Although these data identify HAS3 as a
regulator of tumor growth, there are no data unveiling the mo-
lecular mechanism(s) regulating its expression in tumor cells.
Our data unveils that HAS3 expression is under control of the
transcription factor ΔNp63.
Regarding the HA catabolic genes, the role of HYAL proteins
during tumorigenesis is controversial, acting as tumor promoters
or suppressors, likely reflecting the different biological activities
exerted by the HA catabolic products. Interestingly, HYAL-
2 produces highly angiogenic and protumorigenic HA polymers
(35), which are subsequentially degraded by HYAL-1 in tetra-
saccharides (7). Therefore, it is possible that ΔNp63, by inhib-
iting the expression of HYAL-1, maintains the high levels of the
20-kDa protumorigenic fragments of HA.
In addition to regulating enzymes involved in the HA meta-
bolic process, we also showed that ΔNp63 directly regulates the
expression of CD44, the major cell membrane HA receptor.
Although several published studies have suggested a potential
molecular link between ΔNp63 activity and CD44 in breast
cancer (36, 37), our data demonstrate that ΔNp63 directly con-
trols the expression of CD44 in HNSCC and unveil the biological
significance of the p63-CD44 axis. We focused our attention on
two closely interconnected pathways, which are functionally re-
lated to the HNSCC pathobiology: the EGF-R signaling and the
regulation of the expression of multidrug transporter genes.
EGF-R is overexpressed in more than 90% of HNSCCs, and its
expression has been correlated with poor outcome (13). Previous
reports suggested that ΔNp63 activity is linked to the de-
regulation of EGF-R signaling (18, 38). In detail, it has been
demonstrated that ΔNp63 transcriptionally induces EGF-R
transcription in prostatic cancer cells (38). However, we did not
observe any change of the EGF-R protein levels in HNSCC cells
upon p63 silencing, suggesting that the ΔNp63-dependent reg-
ulation of EGF-R transcription might be tissue-specific, as pre-
viously suggested (38). Conversely, we propose a HA-dependent
mechanism, which molecularly links ΔNp63 activity and EGF-R
signaling. We found that in HNSCC cells the ΔNp63-dependent
effect on EGF-R signaling relies, at least in part, on its ability to
regulate HA metabolism. Interestingly, EGF-R expression is
positively correlated with that of HAS3 in human esophageal
tumors (34) and that the activation of EGF-R led to an induction
of HAS3 expression in ovarian and lung tumor cells (39).
Therefore, ΔNp63-HAS3 pathway might be sustained by a pos-
itive feedback by the EGF-R signaling in HNSCC.
HA-CD44 signaling also promotes resistance to multiple an-
tineoplastic agents, including cisplatin, methotrexate, and doxo-
rubicin (40, 41). We found that the regulation of HA metabolism
and signaling mediates, at least in part, the ΔNp63 prosurvival
action and reduce the cytotoxic effect of cisplatin and doxoru-
bicin in HNSCC. This effect is likely mediated by the regulation
of the expression of the ABCC1 transporter (also known as
MRP1) by the ΔNp63-HA pathway. Elevated ABCC1 expression
levels have been detected in many hematopoietic and solid tu-
mors, and a significant statistical association of high ABCC1
protein levels with poor response in prechemotherapy biopsies of
esophageal adenocarcinoma patients has been reported (42).
However, the molecular mechanisms regulating ABCC1 ex-
pression in human tumors are not well known. We found that
ΔNp63 or HAS3 depletion decreases the expression of ABCC1.
Importantly, both HAS3 and ΔNp63 expression are positively
Fig. 5. ΔNp63-HA pathway regulates HNSCC chemoresistance, and it is a
negative prognostic factor of HNSCC patient survival. (A) FaDu cells trans-
fected with scramble (SCR), p63 (sip63), or HAS3 siRNA oligos (siHAS3) were
treated with doxorubicin (0.4 μM) for 48 h. Cells were then stained with
propidium iodide (PI) and fluorodiacetate (FDA), and the percentage of
apoptotic cells was determined by FACS (Left). Data are shown as the
mean ± SD of three biological replicates (n = 3). **P < 0.01. In parallel, ly-
sates obtained from treated cells were immunoblotted for the indicated
proteins (Right). (B) SCC-9 cells were lentivirally infected with empty or
ΔNp63-expressing particles. Forty-eight hours after infection, cells were
concomitantly treated with doxorubicin (0.4 μM) and 4-MU (0.3 mM) for
48 h, and then cell viability was measured by Celltiter-Glo. Data are shown as
the mean ± SD of three technical replicates (n = 3). *P ≤ 0.05. (C) A253 cells
were transfected with SCR, sip63, or siHAS3, and 48 h after transfection,
ABCC1 mRNA levels were measured by qRT-PCR. Data are shown as the
mean ± SD of three technical replicates (n = 3, PCR runs) and are repre-
sentative of two independent experiments (n = 2 biological replicates). *P <
0.05. (D) Patient samples from the TCGA cohort were clustered into two
groups displaying low and high TP63 and HAS3 expression, respectively, and
analyzed for survival (P value: 0.0068). Clustered expression values relative to
mean expression are shown in the heat map Pearson’s correlation coefficient
(PCC): 0.5959; P value: 9.9639e-51. (E) Schematic model of the ΔNp63-me-
diated regulation of the HA metabolism and signaling.
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correlated with ABCC1 expression levels in human HNSCC pri-
mary tumors. Although we cannot rule out that the prosurvival
effect of ΔNp63 can be due to additional pathways, including the
HA-dependent modulation of EGF-R signaling proposed here,
our data established the existence of a functional connection be-
tween ΔNp63 activity, HA metabolism, and drug fluxes that can
enhance the intrinsic chemoresistance of HNSCC. Alteration of
this circuit would impinge on the capacity of tumor cells to re-
spond to chemotherapy and, therefore, should impact the survival
rate of HNSCC patients. Accordingly, we found that in HNSCC
patients, the p63-HAS3 axis is a negative prognostic factor of
patient survival and it might be thus functionally important to
regulate tumor progression.
Materials and Methods
Human HNSCC Tumor Tissues. HNSCC TMA was purchased by US Biomax, Inc
(HN802a). TMA slide includes 61 cases of squamous cell carcinoma, 7 adenoid
cystic carcinoma, 1 each of adenocarcinoma andmucoepidermoid carcinoma,
plus 10 normal tissues. Score of each tumor samples was calculated as de-
scribed in detail in Supporting Information. HNSCC tissue sample shown in
Fig. S4D has been utilized under approval by the institutional review board
of University Hospital “Policlinico Tor Vergata” with prior patient consent.
Cell Lines. HNSCC and 293T cells were purchased from ATCC and routinely
tested for mycoplasma contaminations. Culture condition, drug treatment,
siRNA transfection, lentiviral infection, ChIP-PCR, RNA analysis, luciferase
assay, apoptosis detection, immunofluorescence, HA measurement, and
Western blotting techniques are all described in Supporting Information.
Details of all other methods are also described in Supporting Information.
Ethics Statement. Animals were subjected to experimental protocols (au-
thorization no. 872/2015-PR) approved by the Veterinary Department of the
Italian Ministry of Health, and experiments were conducted according to the
ethical and safety rules and guidelines for the use of animals in biomedical
research provided by the relevant Italian law and European Union Directive
(Italian Legislative Decree 26/2014 and 2010/63/EU) and the International
Guiding Principles for Biomedical Research involving animals (Council for the
International Organizations of Medical Sciences, Geneva). All adequate
measures were taken to minimize animal pain or discomfort.
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